{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:10:16Z","timestamp":1773126616036,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,10]]},"DOI":"10.7759\/cureus.52032","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T16:55:20Z","timestamp":1704905720000},"source":"Crossref","is-referenced-by-count":4,"title":["Two Cases of Acute Diverticulitis Following Ocrelizumab Infusion in Patients With Multiple Sclerosis"],"prefix":"10.7759","author":[{"given":"Nicholas","family":"Vigilante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cris S","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01672-9","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"82","author":"Lamb YN","year":"2022","unstructured":"Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022, 82:323-34. 10.1007\/s40265-022-01672-9","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2021.0582","article-title":"Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis","volume":"34","author":"Barnes A","year":"2021","unstructured":"Barnes A, Hofmann D, Hall LA, Klebe S, Mountifield R. Ocrelizumab-induced inflammatory bowel disease-like illness characterized by esophagitis and colitis. Ann Gastroenterol. 2021, 34:447-8. 10.20524\/aog.2021.0582","journal-title":"Ann Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa057","article-title":"First case of refractory colitis caused by ocrelizumab","volume":"26","author":"Sunjaya DB","year":"2020","unstructured":"Sunjaya DB, Taborda C, Obeng R, Dhere T. First case of refractory colitis caused by ocrelizumab. Inflamm Bowel Dis. 2020, 26:e49. 10.1093\/ibd\/izaa057","journal-title":"Inflamm Bowel Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8858378","article-title":"Ocrelizumab-induced severe colitis","volume":"2020","author":"Lee HH","year":"2020","unstructured":"Lee HH, Sritharan N, Bermingham D, Strey G. Ocrelizumab-induced severe colitis. Case Rep Gastrointest Med. 2020, 2020:8858378. 10.1155\/2020\/8858378","journal-title":"Case Rep Gastrointest Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.043","article-title":"P096 De novo colitis after ocrelizumab therapy","volume":"158","author":"Akram A","year":"2020","unstructured":"Akram A, Valasek M, Patel D. P096 De novo colitis after ocrelizumab therapy. Gastroenterology. 2020, 158:S1-S2. 10.1053\/j.gastro.2019.11.043","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-252140","article-title":"Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis","volume":"15","author":"Malloy R","year":"2022","unstructured":"Malloy R, Fernandes R, Begun J, An YK. Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis. BMJ Case Rep. 2022, 15:e252140. 10.1136\/bcr-2022-252140","journal-title":"BMJ Case Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000709112.86831.18","article-title":"Ocrelizumab-induced colitis: a case report","volume":"115","author":"Tuqan W","year":"2020","unstructured":"Tuqan W, Siddiqi F, Ray A. Ocrelizumab-induced colitis: a case report. Am J Gastroenterol. 2020, 115:S913. 10.14309\/01.ajg.0000709112.86831.18","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2021.100013","article-title":"Perforated diverticulitis associated with ocrelizumab infusion","volume":"1","author":"Mehta DG","year":"2021","unstructured":"Mehta DG, Wundes A, Strate LL, Romba MC. Perforated diverticulitis associated with ocrelizumab infusion. Neuroimmunol Rep. 2021, 1:100013. 10.1016\/j.nerep.2021.100013","journal-title":"Neuroimmunol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.102","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"26","author":"Hauser SL","year":"2018","unstructured":"Hauser SL, Kappos L, Montalban X, et al.. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Mult Scler Relat Disord. 2018, 26:264. 10.1016\/j.msard.2018.10.102","journal-title":"Mult Scler Relat Disord"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211035740","article-title":"Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: a nonrandomized controlled trial","volume":"28","author":"Weinstock-Guttman B","year":"2022","unstructured":"Weinstock-Guttman B, Bermel R, Cutter G, et al.. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: a nonrandomized controlled trial. Mult Scler. 2022, 28:790-800. 10.1177\/13524585211035740","journal-title":"Mult Scler"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181952888","article-title":"Diverticulitis in the United States: 1998-2005: changing patterns of disease and treatment","volume":"249","author":"Etzioni DA","year":"2009","unstructured":"Etzioni DA, Mack TM, Beart RW Jr, Kaiser AM. Diverticulitis in the United States: 1998-2005: changing patterns of disease and treatment. Ann Surg. 2009, 249:210-7. 10.1097\/SLA.0b013e3181952888","journal-title":"Ann Surg"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser SL","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, et al.. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021, 97:e1546-59. 10.1212\/WNL.0000000000012700","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30786","article-title":"Diverticulitis and diverticulosis of the appendix: a case series","volume":"14","author":"Lesi OK","year":"2022","unstructured":"Lesi OK, Probert S, Iqbal MR, et al.. Diverticulitis and diverticulosis of the appendix: a case series. Cureus. 2022, 14:e30786. 10.7759\/cureus.30786","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjab488","article-title":"Diverticulitis of the appendix-case report and literature review","volume":"2021","author":"Bujold-Pitre K","year":"2021","unstructured":"Bujold-Pitre K, Mailloux O. Diverticulitis of the appendix-case report and literature review. J Surg Case Rep. 2021, 2021:rjab488. 10.1093\/jscr\/rjab488","journal-title":"J Surg Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01680-y","article-title":"Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity","volume":"28","author":"Uzzan M","year":"2022","unstructured":"Uzzan M, Martin JC, Mesin L, et al.. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022, 28:766-79. 10.1038\/s41591-022-01680-y","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab438","article-title":"Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept","volume":"61","author":"Rempenault C","year":"2022","unstructured":"Rempenault C, Lukas C, Combe B, et al.. Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept. Rheumatology (Oxford). 2022, 61:953-62. 10.1093\/rheumatology\/keab438","journal-title":"Rheumatology (Oxford)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000553","article-title":"Clinical features of rituximab-associated gastrointestinal toxicities","volume":"42","author":"Mallepally N","year":"2019","unstructured":"Mallepally N, Abu-Sbeih H, Ahmed O, Chen E, Shafi MA, Neelapu SS, Wang Y. Clinical features of rituximab-associated gastrointestinal toxicities. Am J Clin Oncol. 2019, 42:539-45. 10.1097\/COC.0000000000000553","journal-title":"Am J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/210951-two-cases-of-acute-diverticulitis-following-ocrelizumab-infusion-in-patients-with-multiple-sclerosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:14:31Z","timestamp":1707509671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/210951-two-cases-of-acute-diverticulitis-following-ocrelizumab-infusion-in-patients-with-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.52032","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,10]]}}}